Management of Hypertension in Patients with Renal Failure

First-Line Therapy

The American College of Cardiology recommends ACE inhibitors or ARBs as first-line antihypertensive agents for patients with renal failure, particularly when albuminuria is present, as they provide both blood pressure control and direct renoprotection beyond their BP-lowering effects 1
ACE inhibitors or ARBs should be initiated as first-line therapy in patients with CKD and severely increased albuminuria, with strong evidence supporting their use regardless of diabetes status 1
For patients with CKD but no albuminuria, RAS inhibitors remain a reasonable treatment option 1

Check serum creatinine and potassium within 2-4 weeks of initiating or increasing RAS inhibitor doses 1
Continue therapy unless creatinine rises >30% within 4 weeks of initiation or dose increase 1
Consider dose reduction or discontinuation only for symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or advanced kidney failure (eGFR <15 mL/min/1.73 m²) 1

Never combine ACE inhibitors, ARBs, and direct renin inhibitors in patients with CKD due to increased adverse events, particularly in those with renal insufficiency or diabetes 2, 1
RAS inhibitors are absolutely contraindicated in pregnancy 1
Use with caution in peripheral vascular disease due to association with renovascular disease 3, 1

In severe renal impairment (eGFR <30 mL/min), loop diuretics should replace thiazide diuretics for volume control, though they are less effective for BP lowering 4, 2
Thiazide or thiazide-like diuretics (chlorthalidone or indapamide) maintain efficacy down to eGFR of 30 mL/min/1.73 m² and should be used in combination with RAS inhibitors 4, 5
Diuretics must be used together with an ACE inhibitor or ARB and a β-blocker for optimal outcomes 4, 2
Dihydropyridine CCBs (amlodipine, felodipine) are safe and effective add-on agents when additional BP lowering is needed beyond RAS inhibitor therapy 1
Avoid non-dihydropyridine CCBs (verapamil, diltiazem) due to negative inotropic effects and potential to worsen heart failure 4, 2, 6
Spironolactone or eplerenone are highly effective for resistant hypertension but require careful monitoring 5, 1
Do not use mineralocorticoid receptor antagonists if serum creatinine ≥2.5 mg/dL (men) or ≥2.0 mg/dL (women), or if potassium ≥5.0 mEq/L 4, 2

Target systolic BP <120 mmHg when tolerated in adults with CKD 1
For patients with moderate-to-severe CKD (eGFR >30 mL/min/1.73 m²), aim for systolic BP 120-129 mmHg if tolerated 1
Alternative target of 130-139 mmHg systolic is acceptable in diabetic or non-diabetic CKD 1

Carvedilol, metoprolol succinate, bisoprolol, or nebivolol are preferred if heart failure with reduced ejection fraction coexists 4, 2
Atenolol requires dose reduction: 50% dose if CrCl 15-35 mL/min, 25% dose if CrCl <15 mL/min 7
α-blockers (doxazosin) should only be used if other agents at maximum doses fail to control BP 4, 2, 6
Clonidine and moxonidine should be avoided due to increased mortality risk in similar patient populations 2, 6
NSAIDs should be used with extreme caution due to effects on BP, volume status, and worsening renal function 4, 2